Almost half of GLP-1 quitters are defying the odds on weight regain
GLP-1 medications have reshaped the conversation around obesity and weight management in ways that few treatments ever have. Drugs like semaglutide and tirzepatide became household names almost overnight, celebrated for their ability to drive significant weight loss in ways that diet and exercise alone often cannot. But a pressing question has followed their rise, which […]
Type 2 diabetes risk grows with age
Type 2 diabetes is among the most common and consequential chronic conditions in the United States and a startling number of people living with it have no idea. According to the Centers for Disease Control and Prevention, 27.6 million of the 40.1 million Americans with diabetes remain undiagnosed. That gap exists largely because the condition […]
Understanding the risks of sulfonylureas in diabetes management
Sulfonylureas, a common class of medications for type 2 diabetes, have been linked to a higher long-term risk of impaired awareness of hypoglycemic episodes, according to a recent study from Taiwan. This article explores the findings and implications of this research for those managing diabetes. Key findings from the study Increased risk over time: The […]
Exploring the link between type 2 diabetes medications and reduced cancer risk
Recent studies have shed light on the potential benefits of certain type 2 diabetes medications beyond glucose control. Notably, medications classified as glucagon-like peptide receptor agonists (GLP-1RAs), such as Ozempic, have been linked to a reduced risk of several obesity-related cancers. Key findings from recent research A study published in JAMA Network Open highlights that […]
Understanding the rise in strokes among younger adults
Recent findings from the Centers for Disease Control and Prevention (CDC) indicate a concerning increase in stroke incidents among Americans under 65. Over the past decade, the risk has escalated by approximately 15%, with a notable rise in stroke risk factors such as obesity and type 2 diabetes among younger adults. What is a stroke? […]
Rybelsus vs. Ozempic: Which is right for you?
Interest in glucagon-like peptide 1 agonists (GLP-1), a class of type 2 diabetes drugs that help manage blood sugar and may lead to weight loss, continues to grow. Two medications that often come up in this conversation are Rybelsus and Ozempic. Though both are manufactured by Novo Nordisk and contain semaglutide as the main active […]